CytomX Therapeutics' P/S lags behind the industry despite a ...
CytomX Therapeutics' P/S lags behind the industry despite a strong price move. Its shrinking revenue outlook and poor forecast compared to industry growth justify its low P/S ratio. These conditions may continue to hinder share price growth.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment